Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 12 04:00PM ET
77.31
Dollar change
+0.94
Percentage change
1.23
%
IndexS&P 500 P/E61.45 EPS (ttm)1.26 Insider Own1.03% Shs Outstand157.64M Perf Week8.22%
Market Cap12.18B Forward P/E38.18 EPS next Y2.02 Insider Trans-0.88% Shs Float155.97M Perf Month0.55%
Income202.97M PEG11.05 EPS next Q0.50 Inst Own101.71% Short Float3.22% Perf Quarter12.35%
Sales1.15B P/S10.55 EPS this Y-10.53% Inst Trans1.97% Short Ratio4.55 Perf Half Y5.69%
Book/sh12.79 P/B6.05 EPS next Y13.72% ROA7.63% Short Interest5.02M Perf Year-8.63%
Cash/sh0.92 P/C83.84 EPS next 5Y5.56% ROE10.40% 52W Range51.79 - 89.91 Perf YTD0.19%
Dividend Est.0.25 (0.33%) P/FCF48.51 EPS past 5Y16.30% ROI8.13% 52W High-14.01% Beta1.29
Dividend TTM0.32 (0.41%) Quick Ratio2.88 Sales past 5Y12.76% Gross Margin66.96% 52W Low49.28% ATR (14)2.01
Dividend Ex-DateMay 10, 2024 Current Ratio4.08 EPS Y/Y TTM-25.45% Oper. Margin21.92% RSI (14)63.68 Volatility2.94% 2.52%
Employees3050 Debt/Eq0.25 Sales Y/Y TTM2.73% Profit Margin17.58% Recom1.81 Target Price84.47
Option/ShortYes / Yes LT Debt/Eq0.24 EPS Q/Q-29.65% Payout18.16% Rel Volume1.20 Prev Close76.37
Sales Surprise3.86% EPS Surprise6.01% Sales Q/Q3.16% EarningsMay 01 BMO Avg Volume1.10M Price77.31
SMA205.33% SMA500.90% SMA2009.91% Trades Volume1,322,089 Change1.23%
Date Action Analyst Rating Change Price Target Change
May-22-24Downgrade Citigroup Buy → Neutral $85
Feb-08-24Initiated Scotiabank Sector Outperform $80
Feb-02-24Downgrade Stifel Buy → Hold $65
Dec-07-23Initiated UBS Buy $80
Aug-28-23Initiated William Blair Outperform
Jan-10-23Upgrade Wells Fargo Underweight → Equal Weight $90
Dec-14-22Initiated Deutsche Bank Buy $100
Dec-12-22Upgrade Citigroup Neutral → Buy $81.25 → $100
Dec-07-22Initiated RBC Capital Mkts Sector Perform $89
Aug-25-22Initiated Credit Suisse Outperform $465
Jul-12-24 06:58PM
Jul-09-24 06:00AM
Jul-02-24 07:06PM
May-31-24 07:00AM
May-30-24 07:00AM
07:00AM Loading…
May-29-24 07:00AM
May-23-24 10:26AM
07:00AM
May-22-24 07:00AM
May-20-24 01:34PM
May-14-24 04:49AM
May-08-24 07:00AM
May-07-24 07:00AM
May-06-24 05:57AM
May-02-24 11:40AM
11:31AM Loading…
11:31AM
10:49AM
10:34AM
08:17AM
08:00AM
03:11AM
May-01-24 04:54PM
02:05PM
01:52PM
12:08PM
11:10AM
09:30AM
08:36AM
07:51AM
07:40AM
07:29AM Loading…
07:29AM
06:30AM
06:30AM
Apr-30-24 07:00AM
Apr-29-24 10:38AM
09:39AM
07:00AM
Apr-26-24 07:00AM
Apr-24-24 10:01AM
Apr-23-24 07:00AM
Apr-10-24 07:00AM
Apr-08-24 07:00AM
Apr-03-24 07:00AM
Apr-01-24 07:00AM
Mar-28-24 09:00AM
08:39AM
Mar-22-24 07:00AM
Mar-18-24 08:01PM
Mar-17-24 08:50AM
Mar-12-24 07:00AM
Mar-11-24 07:00PM
Mar-06-24 07:00AM
Feb-23-24 06:15AM
Feb-13-24 08:00AM
Feb-02-24 10:47AM
04:45AM
Feb-01-24 12:57PM
07:51AM
07:07AM
06:30AM
06:30AM
Jan-29-24 07:00AM
Jan-25-24 07:00AM
Jan-24-24 07:00AM
Jan-21-24 01:16PM
Jan-16-24 07:00AM
Jan-05-24 07:00AM
Jan-04-24 07:00AM
Dec-21-23 07:00AM
Dec-20-23 07:00AM
Dec-14-23 07:00AM
Dec-01-23 01:32AM
Nov-27-23 07:00AM
Nov-13-23 07:00AM
Nov-02-23 07:00AM
Nov-01-23 10:44AM
Oct-31-23 07:53AM
07:27AM
06:30AM
06:30AM
Oct-25-23 03:42PM
09:00AM
Oct-22-23 10:30AM
Oct-20-23 05:01AM
Oct-19-23 07:00AM
Oct-16-23 07:00AM
Oct-10-23 07:00AM
Oct-03-23 09:45AM
Sep-28-23 06:00AM
Sep-27-23 07:00AM
Sep-26-23 07:00AM
Sep-25-23 07:00AM
Sep-23-23 09:00AM
Sep-19-23 02:00AM
Sep-18-23 07:32PM
10:14AM
Sep-08-23 11:35AM
Sep-06-23 12:04PM
Aug-28-23 07:32PM
01:03PM
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the Protein Sciences, and Diagnostics and Genomics segments. The Protein Sciences segment develops and manufactures purified proteins, and reagent solutions. The Diagnostics and Genomics segment develops and manufactures diagnostic products. The company was founded in 1976 and is headquartered in Minneapolis, MN.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HIGGINS JOHN LDirectorJul 08 '24Option Exercise22.956,000137,70042,608Jul 10 04:35 PM
HIGGINS JOHN LDirectorMay 14 '24Option Exercise22.954,00091,80040,608May 16 04:17 PM
HIGGINS JOHN LDirectorMay 14 '24Sale83.844,000335,37736,608May 16 04:17 PM
Nusse RoelandDirectorMar 07 '24Sale76.9810,400800,62743,097Mar 11 04:04 PM
Hippel JamesCFODec 19 '23Option Exercise31.2647,2891,478,254104,850Dec 21 04:06 PM
Nusse RoelandDirectorAug 30 '23Option Exercise22.4032,000716,80060,811Sep 01 04:06 PM
Nusse RoelandDirectorAug 30 '23Sale80.328,939717,95951,872Sep 01 04:06 PM
Kelderman KimPres. Diagnostics & GenomAug 24 '23Option Exercise47.602,10099,96021,225Aug 28 04:19 PM
Kummeth Charles R.Chief Executive OfficerAug 15 '23Option Exercise0.0017,63201,286,944Aug 17 04:14 PM
Kummeth Charles R.Chief Executive OfficerAug 05 '23Option Exercise0.0051,51601,310,282Aug 08 05:31 PM
Hippel JamesCFOAug 05 '23Option Exercise0.0012,876063,896Aug 08 05:29 PM
Kelderman KimPres. Diagnostics & GenomAug 05 '23Option Exercise0.008,060023,264Aug 08 05:28 PM
Kummeth Charles R.Chief Executive OfficerJul 21 '23Sale88.3680,0007,069,0241,258,766Jul 25 05:27 PM